St. Mary's Cyber Knife Program Participating in Multi Site Study

Special to HuntingtonNews.Net
St. Mary's Cyber Knife Program Participating in Multi Site Study

Study Will Examine Invasive, Non Invasive Lung Cancer Options

Huntington, WV, (HNN) – St. Mary’s Regional Cancer Center announced today it will participate in the national phase III clinical trial STARS (Stereotactic Radiosurgery vs. Surgery) comparing surgical and nonsurgical treatment for early-stage NSCLC (Non-Small Cell Lung Cancer), the most common form of lung cancer.

According to the American Cancer Society, lung cancer is the leading cause of cancer deaths with more than 1,000,000 new cases annually worldwide.

The premise for the STARS trial is positive research findings on the use of noninvasive radiosurgery to treat inoperable lung cancer. A 2010 JAMA study found radiosurgery provided more than double the rate of primary tumor control in inoperable patients than conventional radiotherapy; 97 percent of radiosurgery patients responded favorably at three years post-treatment.

Additional research conducted at Georgetown University Hospital and published in a 2009 issue of Journal of Hematology & Oncology found treatment with the CyberKnife® Robotic Radiosurgery System® led to 100 percent survival after three years in inoperable lung cancer patients with good lung function before treatment. CyberKnife radiosurgery offers a non-invasive, pain-free way to treat tumors anywhere in the body by precisely delivering high-dose radiation and can automatically track, detect and correct for tumor and patient movement in real-time throughout treatment.

“We are excited about the promise of radiosurgery and the opportunity to investigate its potential to treat an even larger patient population,” said Dr. Sanjeev Sharma, M.D., radiation oncologist at St. Mary’s Regional Cancer Center. “We are encouraging those with operable lung cancer who meet the study qualifications to take advantage of the availability of this innovative treatment offered in their local community.”

The STARS trial, led by Jack Roth, M.D. Department of Thoracic & Cardiovascular Surgery at M.D. Anderson Cancer Center in Houston, Texas and sponsored by Accuray Inc. will randomly assign participants to traditional surgery or CyberKnife radiosurgery and will compare results at three years post-treatment.

The study will enroll up to 1,200 patients in multiple sites around the world including M.D. Anderson, Parkview Comprehensive Cancer Care, Stanford University, St. Louis University, Guangxi Ruikang Hospital and Tianjin Cancer Institute and Hospital in China. To qualify, prospective participants must be 18 years or older and have Stage 1 NSCLC. Additional diagnostic testing will be required to determine qualification. For more information call St. Mary’s Regional Cancer Center at (304) 399-7460.